trending Market Intelligence /marketintelligence/en/news-insights/trending/zno_1rqy2aqk8daf3kzama2 content esgSubNav
In This List

Astellas, Aquinox enter license deal for bladder pain drug

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Astellas, Aquinox enter license deal for bladder pain drug

Tokyo's Astellas Pharma Inc. and Vancouver, British Columbia's Aquinox Pharmaceuticals Inc. entered a license deal for the latter's lead drug candidate rosiptor.

Under the deal, Astellas will receive the exclusive right to develop and sell rosiptor in Japan and other countries in the Asia-Pacific, including South Korea, Australia, Taiwan, Indonesia and Malaysia but excluding China and India.

Aquinox will receive $25 million up front under the deal. The company is also eligible for up to $130 million in milestone payments, as well as royalties on future rosiptor sales.

Rosiptor is in clinical development for interstitial cystitis/bladder pain syndrome, characterized by discomfort or pain related to the urinary bladder.